



Adding Smiles To Life

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C 1, Block G,
Bandra - Kurla Complex,
Bandra (E),
Mumbai - 400 051.

Company Symbol: QMSMEDI

ISIN: INEOFMW01018

Sub: Press Release - Unaudited Financial Results of the Company for the quarter ended December 31, 2023

Pursuant to Regulation 30 of the SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, enclosed herewith the copy of the Press Release with regard to the Unaudited Financial Results of the Company for the quarter ended December 31, 2023.

A copy of the press release is also uploaded on the Company's website.

Kindly take the same on your records and oblige.

Thanking you,

Yours truly,

FOR QMS MEDICAL ALLIED SERVICES LIMITED

**TORAL BHADRA
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO.: A56927
DATE: FEBRUARY 15, 2024
PLACE: MUMBAI**

QMS Medical Allied Services Ltd.

📍 1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.

☎ +91-022 - 6288 1111 🌐 www.qmsmas.com

CIN: U33309MH2017PLC299748; Email Id: mm@qmsmas.com



QMS Surging Ahead with a Remarkable YoY Growth, Achieving a Striking 444 Bps Growth in EBITDA Margin for 9M FY24

Mumbai 15th February 2024 – QMS Medical Allied Services Limited, engaged in the marketing and distribution of a wide range of medical products, as well as emphasizing Patient Services Programs, has announced its Unaudited Financial Results for 9M & Q3 FY24.

Particulars (₹ Cr)	9M FY24	9M FY23	Y-o-Y
Total Income	90.18	73.22	23.16 %
EBITDA	14.74	8.71	69.15 %
EBITDA (%)	16.34	11.90	444 BPS
Net Profit	7.46	4.81	55.18 %
NPM (%)	8.28	6.57	171 BPS
EPS (₹)	4.18	3.03	37.95 %

Commenting on the performance, **Mr. Mahesh Makhija, Chairman and Managing Director, mentioned**, “In assessing our performance over the past nine months, we are pleased to announce that we are navigating a positive trajectory. The investments and dedicated efforts in our business verticals, specifically in Patient Services Programs and Q devices in preceding financial years, are now yielding tangible results, underscoring our impressive growth. This accomplishment stands as a testament to our unwavering commitment.

These strategic initiatives are positioned not only to strengthen our current position but also to provide a significant boost for the rest of FY24 and beyond. Looking ahead, the recent capital infusion through convertible equity share warrants and equity shares on a preferential basis is anticipated to act as a catalyst for the company's growth and development. A positive outlook on the future is maintained, encouraged by our continuous achievements and smart strategies. Confidence is placed in the trajectory of continued success and the sustained growth that lies ahead.”

About QMS Medical Allied Services Limited

Incorporated in 2017, QMS Medical Allied Services Limited is a leading medical and healthcare entity in India, specializing in the marketing and distribution of essential devices and accessories. With a focus on quality and affordability, the company offers a wide range of devices under the "Q-Devices" brand, including glucometers, pulse oximeters, thermometers, monitors, anatomical sets, neurology kits, and orthopaedic aids. The company's expertise extends to medical consumables such as disinfectants, filters, and wound care products. Its extensive distribution network ensures broad accessibility, while strategic marketing efforts bolster brand recognition and expansion.

QMS MAS emerges as a prominent healthcare services provider in India, deeply committed to advancing preventive healthcare. A significant aspect is its second vertical, offering Patient Service Programs to the public. These programs provide consumers unprecedented access to specialized screening tests across the country. They serve as a driver to of preventative healthcare amongst all Indians and will eventually drive down the healthcare costs arising due to chronic disease medication and hospitalization.

In FY23, the Company has reported Total Revenue of ₹ 104.04Cr with EBITDA of ₹ 12.07Cr & Net Profit of ₹ 6.38Cr.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



Kirin Advisors Private Limited

Sunil Mudgal - Director

sunil@kirinadvisors.com

+91 98692 75849

www.kirinadvisors.com